ArticleCardiorenal medicine2026
Kidney Transplant Outcomes in Patients with and without Type II Diabetes Mellitus.
Article in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to estimate the impact of type II diabetes (DM-II) on kidney transplant outcomes and graft utility.
methodsA nationwide, registry-based study compares outcomes for all primary kidney transplantations performed between 2000 and 2022 in the Netherlands in DM-II patients (761 deceased and 364 living donor procedures) with nondiabetic controls.
resultsShort-term (≤90 days) transplant outcomes for living donor procedures were similar for DM-II and nondiabetic controls. Deceased donor transplantations in DM-II patients were associated with an increased incidence of delayed graft function (p < 0.0002), and a doubling of 90-day mortality (HR: 2.19 [95% CI: 1.49-3.23], p < 0.0001). Evaluation of long-term graft survival, with death as competing risk, indicated an equal (sub-distribution hazard rate [sHR] 0.95 [0.74-1.23]), respectively, compromised (sHR 1.91 [1.37-2.65]; p < 0.001) survival for grafts from deceased or living donors. DM-II profoundly impacted recipient survival (HR for death, respectively, 1.63 [1.45-1.82] and 1.81 [1.51-2.17]; p < 0.001) for recipients of a deceased or living donor graft (nondiabetic recipient is reference), with cardiovascular event and infection as dominant causes of death. The compromised recipient survival profoundly impacted the utility of kidney transplantations (p < 0.001).
conclusionsDespite excellent graft survival, the efficacy of kidney transplantations in DM-II patients is compromised by reduced recipient survival. Cause of death distribution suggests a role for immunosuppressive regimens in the excess mortality observed. A shift in focus from optimized transplant to optimized patient survival is warranted for DM-II patients. Moreover, the conflict between increasing incidences of DM-II, a lower transplant utility, but persistent donor organ shortages, calls for development of novel organ allocation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.